---
schema_version: "secwatch.filing_event.v1"
accession: "0001171843-26-000154"
form_type: "8-K"
ticker: "BCRX"
cik: "0000882796"
company_name: "BIOCRYST PHARMACEUTICALS INC"
filed_at: "2026-01-09T23:59:59+00:00"
generated_at: "2026-05-16T11:08:26.944029+00:00"
event_type: "other"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# BioCryst increases ORLADEYO WAC by ~9% to $48,488 per 28-day pack

## Summary
- Effective January 9, 2026, WAC for ORLADEYO (berotralstat) raised from $44,484.33 to $48,487.92 per 28-day pack.
- The price increase applies to both the 150mg and 110mg capsule strengths.
- BioCryst's sole marketed product ORLADEYO is approved for hereditary angioedema prophylaxis.

## SEC filing metadata
- accession: 0001171843-26-000154
- form_type: 8-K
- ticker: BCRX
- cik: 0000882796
- company_name: BIOCRYST PHARMACEUTICALS INC
- filed_at: 2026-01-09T23:59:59+00:00
- event_type: other
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 7.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/882796/000117184326000154/0001171843-26-000154-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/882796/000117184326000154/f8k_010826.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001171843-26-000154
- JSON: https://secwatch.observer/filing/0001171843-26-000154.json
- Plain text: https://secwatch.observer/filing/0001171843-26-000154.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.